ANTICANCER FUSION PROTEIN

A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with th...

Full description

Saved in:
Bibliographic Details
Main Authors TESKA-KAMINSKA MALGORZATA IZABELA, PIECZYKOLAN ANNA MARIA, JAWORSKI ALBERT ROBERT, ZEREK BARTLOMIEJ MACIEJ, PIECZYKOLAN JERZY SZCZEPAN, SZYMANIK MICHAL, RÓZGA PIOTR, PAWLAK SEBASTIAN
Format Patent
LanguageEnglish
Published 12.02.2015
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with the amino acid hTRAIL281; and domain (b) which is a sequence of an effector peptide inhibiting protein synthesis, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.
Bibliography:Application Number: US201214361279